R/R melanoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

When the cells (melanocytes) that produce the melanin that gives skin color malfunction, melanoma forms. In a normal, orderly development, skin cells push unhealthy, older cells toward the skin's surface, where they eventually die and fall off. Melanoma incidence is increasing in developed countries with a preponderance of people with fair skin. After the initial therapy, the stage of the primary melanoma, the prior therapies, the site of the recurrence, and other factors all influence how the melanoma is treated. Melanoma can come back in the skin near the original tumor, and in rare cases, it can even grow in the surgical scar.

Description

Melanocytes, which are the cells responsible for the skin's color and melanin production, malfunction to cause melanoma. In a normal, orderly development, skin cells push unhealthy, older cells toward the skin's surface, where they eventually die and fall off. The first sign of melanoma is frequently a change in the size, color, texture, or shape of an already-existing mole. A new mole, however, might also be a sign of melanoma. Anyone who notices any changes to their skin should let their doctor know. Only by removing tissue and checking it for cancer cells can melanoma be identified. Melanomas can have many different appearances. In more advanced melanoma, the texture of the mole may change. Skin on the surface may deteriorate and look scraped. Different melanoma types can be identified by their radial and vertical growth phases. In the radial growth phase, malignant cells expand radially in the epidermis. Most melanomas eventually progress to the vertical growth phase, where the cancerous cells invade the dermis and develop the ability to metastasize. Melanoma is a cancer of the skin that primarily affects adults, and more than half of cases occur in regions of the skin that are normal. Melanoma can manifest itself anywhere, including on mucosal surfaces and the uvea, but it typically affects women's extremities more than men's. It typically has an impact on the head and neck or the trunk in men.

R/R melanoma (Epidemiology)

Melanoma incidence is increasing in developed countries where people with fair skin predominate. In the US, it has grown by more than 320% since 1975. The death rate in the US has, however, decreased by nearly 30% over the previous ten years since 2011, when ten new targeted or immunotherapy drugs received approval. Despite the fact that the US now has a 5-year survival rate of 93%. The survival rate for stage IV disease is still 29%. eight%. Melanoma is most likely to develop in older, white men with a diagnosis age of 65. The incidence varies depending on where the person lives. The white populations in Australia, New Zealand, South Africa, and the southern United States have the highest rates, while the Asian populations in Hong Kong, Singapore, China, India, and Japan have the lowest rates. This suggests that white people are significantly more at risk if they live in sunny areas. Although more people are developing head and neck lesions than trunk and extremity lesions, the incidence of melanoma is increasing in the United States. However, survival rates are increasing. In the US in 1995, there were an estimated 34,100 new cases of melanoma, which claimed the lives of 7,200 people. From 27,600 to 6,300 new cases and fatalities were reported in 1990. In addition, there were 44,200 new cases of melanoma in 1999, and there were also approximately 7,300 reported deaths from the disease. The number of fatal cases and new cases of melanoma in the US in 2008 is expected to be 8,420 and 62,480, respectively. Melanoma currently affects 1 in 50 white people, 1 in 1,000 Black people, and 1 in 200 Hispanic people in the US.

R/R melanoma -Current Market Size & Forecast Trends

The market for relapsed or refractory (R/R) melanoma is projected to grow significantly, with estimates indicating a value of approximately USD 3.9 billion in 2023. This market is expected to reach around USD 8.9 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.93% during the forecast period from 2024 to 2034. The growth is driven by advancements in immunotherapy and targeted therapies, including the development of BRAF and MEK inhibitors, which provide effective treatment options for patients. Additionally, the increasing incidence of melanoma and ongoing research into novel therapies are expected to further enhance market dynamics. North America is anticipated to be the largest market due to its advanced healthcare infrastructure and significant investment in cancer research. Overall, the R/R melanoma market is well-positioned for substantial growth through 2035 as treatment options continue to evolve and improve patient outcomes.

After the initial therapy, the stage of the primary melanoma, the prior therapies, the site of the recurrence, and other factors all influence how the melanoma is treated. Melanoma can come back in the skin near the original tumor, and in rare cases, it can even grow in the surgical scar. Like primary melanoma, these local (skin) recurrences are typically surgically treated. One option in this case might be a sentinel lymph node biopsy (SLNB). If melanoma returns in nearby lymph vessels in or just below the skin (a situation known as an "in-transit recurrence"), it should be removed if at all possible. Other options include administering injections of the T-VEC vaccine (Imlygic), the BCG vaccine, or interleukin-2 (IL-2) or using imiquimod cream. Isolated limb perfusion or isolation limb infusion, which confines chemotherapy treatment to the affected limb, is an additional option for treating melanomas on the arm or leg. Chemotherapy, targeted therapy, and immunotherapy are other potential treatments for melanomas with a BRAF or C-KIT gene change. If some of the nearby lymph nodes weren't completely removed during the initial treatment, the melanoma might come back there. If feasible, lymph node dissection is used to treat lymph node recurrence; adjuvant treatments such as radiation therapy, immunotherapy, or targeted therapy (for cancers with BRAF gene mutations) may then be used. In place of surgery, patients may receive radiation therapy or systemic therapy (chemo, immunotherapy, or targeted therapy). Melanoma can come back in obscure parts of the body. Almost any organ could be affected. Melanoma most frequently recurs in the liver, brain, lungs, and bones. Treatment for these recurrences usually follows the same path as that for stage IV melanoma. Melanomas on the arm or leg that recur can be treated with isolated limb perfusion/infusion chemotherapy. Brain-returning melanoma can be difficult to treat. Sometimes a single tumor can be removed through surgery. Receiving radiation therapy for the brain, such as stereotactic radiosurgery or whole brain radiation therapy, may also be advantageous. Systemic treatments could include chemotherapy, targeted therapy, or immunotherapy.

Report Highlights

R/R melanoma - Current Market Trends

R/R melanoma - Current & Forecasted Cases across the G8 Countries

R/R melanoma - Market Opportunities and Sales Potential for Agents

R/R melanoma - Patient-based Market Forecast to 2035

R/R melanoma - Untapped Business Opportunities

R/R melanoma - Product Positioning Vis-a-vis Competitors' Products

R/R melanoma - KOLs Insight